Clinical trial
An Investigational Immuno-therapy Study to Investigate the Safety and…
NCT02488759 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT02488759 |
|---|---|
| Title | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors |
| Official title | Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors |
| Acronym | CheckMate358 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Ono Pharmaceutical Co. Ltd Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Various Advanced Cancer |
| Intervention type | Drug |
| Interventions | Nivolumab, Ipilimumab, Relatlimab, Daratumumab |
| Enrollment | 578 |
| Start date | Oct 13, 2015 |
| Primary completion | Mar 19, 2021 |
| Completion | Oct 24, 2022 |
| First posted | Jul 2, 2015 |
| Last update posted | Nov 13, 2023 |
| Countries | Belgium, France, Germany, Japan, Mexico, Netherlands, South Korea, Spain, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: